» Articles » PMID: 19119097

Sampling of Melanocytic Nevi for Research Purposes: a Prospective, Pilot Study to Determine Effect on Diagnosis

Overview
Specialty Dermatology
Date 2009 Jan 3
PMID 19119097
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Research on melanocytic nevi predominantly utilizes formalin-fixed, paraffin-embedded tissue, largely limiting research to morphologic and immunohistochemical observations. Withholding portions of fresh nevus tissue for molecular studies could result in the loss of important diagnostic material.

Objective: This study prospectively evaluated melanocytic nevi for histologic homogeneity to determine if using a portion for research would have affected diagnosis.

Methods: Thirty-three subjects were enrolled in a prospective study in which pigmented lesions were chosen for biopsy on a clinical basis. Lesions were sectioned and each piece submitted in a separate block (mean, 2.7; range 2-5 blocks per lesion). Slides from nevi were examined in two phases. In phase I, sections of nevi were randomized and a diagnosis was rendered for each section of nevus. In phase II, the dermatopathologist reviewed all slides for each nevus as a case, similar to the original interpretation of the lesion provided to the clinician. Diagnoses from phases I and II were compared with the original diagnosis.

Results: Case material included 51 melanocytic lesions from 31 subjects. The phase I diagnosis matched the original diagnosis for 99 of 121 slides that showed a melanocytic lesion (82%). The phase II diagnosis matched the original diagnosis for 45 of 51 specimens (88%).

Limitations: The study was limited by: a small number of specimens; the clinician could have chosen clinically homogeneous nevi for biopsy; effect of interobserver and intraobserver variability on diagnosis.

Conclusions: For the majority of melanocytic nevi in this study, the diagnostic information present in one section of a melanocytic nevus could be extrapolated to the remainder of the specimen without adverse consequences from a diagnostic or therapeutic perspective.

Citing Articles

Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens.

Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C Diagn Pathol. 2013; 8:17.

PMID: 23379971 PMC: 3584735. DOI: 10.1186/1746-1596-8-17.


Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma.

Wu B, Li W, Qian C, Ding W, Zhou Z, Jiang H Tumour Biol. 2012; 34(2):643-8.

PMID: 23179401 DOI: 10.1007/s13277-012-0591-0.


Increased shedding of HU177 correlates with worse prognosis in primary melanoma.

Hamilton H, Rose A, Christos P, Shapiro R, Berman R, Mazumdar M J Transl Med. 2010; 8:19.

PMID: 20178639 PMC: 2837640. DOI: 10.1186/1479-5876-8-19.


Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi.

Goodson A, Florell S, Boucher K, Grossman D J Am Acad Dermatol. 2009; 62(4):591-6.

PMID: 20018406 PMC: 2886801. DOI: 10.1016/j.jaad.2009.06.080.


Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention.

Goodson A, Cotter M, Cassidy P, Wade M, Florell S, Liu T Clin Cancer Res. 2009; 15(23):7434-40.

PMID: 19920101 PMC: 2787788. DOI: 10.1158/1078-0432.CCR-09-1890.